LONDON (Alliance News) - AstraZeneca PLC announced the US FDA has approved a new administration option for acute coronary syndrome patients who are unable to swallow BRILINTA 90 mg tablets whole.
The company said, unlike other P2Y12 inhibitors, BRILINTA has FDA approval to be crushed and administered in water by swallowing or via nasogastric tube.
BRILINTA is an oral antiplatelet treatment for acute coronary syndrome. BRILINTA is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclopentyltriazolopyrimidines.
Shares in AstraZeneca are trading up 0.3% at 4,698.00 pence Monday afternoon.
Copyright RTT News/dpa-AFX